Modeling Assisted In Silico Design of Ligand Molecule for DPP IV in Type II Diabetes Mellitus

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|9|8|764-766

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.9, Iss.8, 2012-10, pp. : 764-766

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

By Holst Jens Juul  

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 155-166

Informa Healthcare

Access to resources Recommend Favorite

Computational Identification of Inhibitors Against DPP-IV for Checking Type-2 Diabetes

By  

Letters in Drug Design & Discovery, Vol. 14, Iss. 1, 2017-01 ,pp. : 66-73

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy

By Gallwitz Baptist  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 723-732

Informa Healthcare

Access to resources Recommend Favorite

Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective

By  

Current Medicinal Chemistry, Vol. 21, Iss. 35, 2014-01 ,pp. : 4013-4045

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging Drug Candidates of Dipeptidyl Peptidase IV (DPP IV) Inhibitor Class for the Treatment of Type 2 Diabetes

By  

Current Drug Targets, Vol. 10, Iss. 1, 2009-01 ,pp. : 71-87

Bentham Science Publishers

Access to resources Recommend Favorite